|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The prognostic significance of the major redox regulator nuclear factor erythroid-2-related factor (NRF2) is recognized in many cancers, but the role of NRF1 is not generally well understood in cancer.
|
31687076 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These data represent that inhibition of NRF1 degradation is a potential therapeutic strategy against cancer.
|
30833558 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Overall, our study provides a framework for manipulating the TIP60-Nrf1 axis to alter proteasome function in various human diseases, including cancer.
|
30559296 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
The prognostic significance of the major redox regulator nuclear factor erythroid-2-related factor (NRF2) is recognized in many cancers, but the role of NRF1 is not generally well understood in cancer.
|
31687076 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These data represent that inhibition of NRF1 degradation is a potential therapeutic strategy against cancer.
|
30833558 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Overall, our study provides a framework for manipulating the TIP60-Nrf1 axis to alter proteasome function in various human diseases, including cancer.
|
30559296 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Promoters of several genes from the KEGG HER2+ breast cancer pathway and 11 signaling pathways linked to 6 hallmarks of cancer contain the NRF1 motif.
|
30128822 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Additionally, NRF1 may orchestrate both MYC and E2F4 to regulate common target genes linked to multiple networks in the development and progression of cancer.
|
30047092 |
2018 |
|
Neuroblastoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In the present study, we focused on the epigenetic effects of TBT and investigated whether TBT decreases NRF-1 expression via epigenetic modifications in SH-SY5Y human neuroblastoma cells.
|
29345269 |
2018 |
|
Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers.
|
30267745 |
2018 |
|
Central neuroblastoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In the present study, we focused on the epigenetic effects of TBT and investigated whether TBT decreases NRF-1 expression via epigenetic modifications in SH-SY5Y human neuroblastoma cells.
|
29345269 |
2018 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers.
|
30267745 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Promoters of several genes from the KEGG HER2+ breast cancer pathway and 11 signaling pathways linked to 6 hallmarks of cancer contain the NRF1 motif.
|
30128822 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Additionally, NRF1 may orchestrate both MYC and E2F4 to regulate common target genes linked to multiple networks in the development and progression of cancer.
|
30047092 |
2018 |
|
Childhood Neuroblastoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In the present study, we focused on the epigenetic effects of TBT and investigated whether TBT decreases NRF-1 expression via epigenetic modifications in SH-SY5Y human neuroblastoma cells.
|
29345269 |
2018 |
|
Childhood Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers.
|
30267745 |
2018 |
|
Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, our data showed that the combination of genome-wide bioinformatic analysis and biological experiments helps to identify the novel NRF-1-regulated genes, which play roles in differentiation of neuroblastoma cells.
|
23219993 |
2013 |
|
Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, we annotated FAM134C, C3orf10, and ENOX1 as NRF-1-regulated genes, which have differential effects on neurite outgrowth in neuroblastoma cells as well as neurons.
|
23939472 |
2013 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, we annotated FAM134C, C3orf10, and ENOX1 as NRF-1-regulated genes, which have differential effects on neurite outgrowth in neuroblastoma cells as well as neurons.
|
23939472 |
2013 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, our data showed that the combination of genome-wide bioinformatic analysis and biological experiments helps to identify the novel NRF-1-regulated genes, which play roles in differentiation of neuroblastoma cells.
|
23219993 |
2013 |
|
Childhood Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, we annotated FAM134C, C3orf10, and ENOX1 as NRF-1-regulated genes, which have differential effects on neurite outgrowth in neuroblastoma cells as well as neurons.
|
23939472 |
2013 |
|
Childhood Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overall, our data showed that the combination of genome-wide bioinformatic analysis and biological experiments helps to identify the novel NRF-1-regulated genes, which play roles in differentiation of neuroblastoma cells.
|
23219993 |
2013 |
|
Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We found that stable or transient expression of full-length alpha-Pal/NRF-1 in human neuroblastoma IMR-32 cells significantly induced neurite outgrowth and increased the length of neurites both in medium containing 10% fetal bovine serum and in serum-free medium.
|
15992771 |
2005 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We found that stable or transient expression of full-length alpha-Pal/NRF-1 in human neuroblastoma IMR-32 cells significantly induced neurite outgrowth and increased the length of neurites both in medium containing 10% fetal bovine serum and in serum-free medium.
|
15992771 |
2005 |
|
Childhood Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We found that stable or transient expression of full-length alpha-Pal/NRF-1 in human neuroblastoma IMR-32 cells significantly induced neurite outgrowth and increased the length of neurites both in medium containing 10% fetal bovine serum and in serum-free medium.
|
15992771 |
2005 |